Quick Answer
Q32 Bio Inc. reported Stockholders Equity of $42.01 million for the year ending 2025.
- Q32 Bio Inc. showed an increase of +640.3% in Stockholders Equity from 2024 to 2025.
- This data is from Q32 Bio Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$49.22 million | Q2 2018: $227.57 million | Q3 2018: $214.18 million | Q1 2019: $174.26 million | Q2 2019: $284.74 million | Q3 2019: $257.82 million | Q1 2020: $226.54 million | Q2 2020: $194.70 million | Q3 2020: $170.22 million | Q1 2021: $200.83 million | Q2 2021: $224.58 million | Q3 2021: $198.57 million | Q1 2022: $266.25 million | Q2 2022: $240.29 million | Q3 2022: $209.06 million | Q1 2023: -$137.24 million | Q2 2023: -$142.72 million | Q3 2023: -$156.45 million | Q1 2024: $48.77 million | Q2 2024: $33.51 million | Q3 2024: $18.30 million | Q1 2025: -$4.01 million | Q2 2025: $4.00 million | Q2 2025: -$12.24 million | Q3 2025: -$18.45 million.
- Over the full 10 years of available data (2016 to 2025), Q32 Bio Inc.'s Stockholders Equity has grown by 524.7%.
- Historical annual values: Fiscal year 2025: $42.01 million | Fiscal year 2024: $5.68 million | Fiscal year 2023: -$182.92 million | Fiscal year 2022: -$130.71 million | Fiscal year 2021: $169.65 million | Fiscal year 2020: $196.00 million | Fiscal year 2019: $258.51 million | Fiscal year 2018: $196.36 million | Fiscal year 2017: -$39.45 million | Fiscal year 2016: -$9.89 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: